You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial

Citation Tools

Article menu

Download PDFPDF

Thursday 06 October 2022 from 15:40 to 17:10
S11 immune system in SLE
S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Humrich J, Cacoub P, Rosenzwajg M, et al
S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial
Lupus Science & Medicine 2022;9:doi: 10.1136/lupus-2022-elm2022.24